Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment

Mimi I. Hu, Ilya Glezerman, Sophie Leboulleux, Karl Insogna, Rasim A. Gucalp, Waldemar Misiorowski, Bennett Yu, Wendy Ying, Rajul K. Jain

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In this single-arm, open-label, proof-of-concept study, HCM patients with albumin-corrected serum calcium (CSC) levels greater than 12.5 mg/dL (Common Terminology Criteria for Adverse Events grade ≥3) despite recent intravenous bisphosphonate treatment received subcutaneous denosumab on days 1, 8, 15, and 29, and then every 4 weeks. The primary endpoint was the proportion of patients with CSC 11.5 mg/dL or less (grade ≤1) within 10 days of denosumab initiation. In a prespecified interim analysis, 15 patients received denosumab (median CSC = 13.6 mg/dL). Time to response and response duration were analyzed with Kaplan-Meier methods. All statistical tests were two-sided. By day 10, 12 patients (80%; 95% exact confidence interval [CI] = 52% to 96%) responded (CSC ≤11.5 mg/dL); median response duration was 26 days. Ten patients (67%; 95% exact CI = 38% to 88%) had complete responses (CSC ≤10.8 mg/dL) by day 10. Denosumab may offer a new treatment option for HCM.

Original languageEnglish (US)
Pages (from-to)1417-1420
Number of pages4
JournalJournal of the National Cancer Institute
Volume105
Issue number18
DOIs
StatePublished - Sep 18 2013

Fingerprint

Diphosphonates
Hypercalcemia
Calcium
Neoplasms
Bone Resorption
Serum
Therapeutics
Confidence Intervals
Coma
Terminology
Serum Albumin
Renal Insufficiency
Denosumab
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. / Hu, Mimi I.; Glezerman, Ilya; Leboulleux, Sophie; Insogna, Karl; Gucalp, Rasim A.; Misiorowski, Waldemar; Yu, Bennett; Ying, Wendy; Jain, Rajul K.

In: Journal of the National Cancer Institute, Vol. 105, No. 18, 18.09.2013, p. 1417-1420.

Research output: Contribution to journalArticle

Hu, Mimi I. ; Glezerman, Ilya ; Leboulleux, Sophie ; Insogna, Karl ; Gucalp, Rasim A. ; Misiorowski, Waldemar ; Yu, Bennett ; Ying, Wendy ; Jain, Rajul K. / Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. In: Journal of the National Cancer Institute. 2013 ; Vol. 105, No. 18. pp. 1417-1420.
@article{3e1981d43ea8403bbd98de7f8b077259,
title = "Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment",
abstract = "Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In this single-arm, open-label, proof-of-concept study, HCM patients with albumin-corrected serum calcium (CSC) levels greater than 12.5 mg/dL (Common Terminology Criteria for Adverse Events grade ≥3) despite recent intravenous bisphosphonate treatment received subcutaneous denosumab on days 1, 8, 15, and 29, and then every 4 weeks. The primary endpoint was the proportion of patients with CSC 11.5 mg/dL or less (grade ≤1) within 10 days of denosumab initiation. In a prespecified interim analysis, 15 patients received denosumab (median CSC = 13.6 mg/dL). Time to response and response duration were analyzed with Kaplan-Meier methods. All statistical tests were two-sided. By day 10, 12 patients (80{\%}; 95{\%} exact confidence interval [CI] = 52{\%} to 96{\%}) responded (CSC ≤11.5 mg/dL); median response duration was 26 days. Ten patients (67{\%}; 95{\%} exact CI = 38{\%} to 88{\%}) had complete responses (CSC ≤10.8 mg/dL) by day 10. Denosumab may offer a new treatment option for HCM.",
author = "Hu, {Mimi I.} and Ilya Glezerman and Sophie Leboulleux and Karl Insogna and Gucalp, {Rasim A.} and Waldemar Misiorowski and Bennett Yu and Wendy Ying and Jain, {Rajul K.}",
year = "2013",
month = "9",
day = "18",
doi = "10.1093/jnci/djt225",
language = "English (US)",
volume = "105",
pages = "1417--1420",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment

AU - Hu, Mimi I.

AU - Glezerman, Ilya

AU - Leboulleux, Sophie

AU - Insogna, Karl

AU - Gucalp, Rasim A.

AU - Misiorowski, Waldemar

AU - Yu, Bennett

AU - Ying, Wendy

AU - Jain, Rajul K.

PY - 2013/9/18

Y1 - 2013/9/18

N2 - Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In this single-arm, open-label, proof-of-concept study, HCM patients with albumin-corrected serum calcium (CSC) levels greater than 12.5 mg/dL (Common Terminology Criteria for Adverse Events grade ≥3) despite recent intravenous bisphosphonate treatment received subcutaneous denosumab on days 1, 8, 15, and 29, and then every 4 weeks. The primary endpoint was the proportion of patients with CSC 11.5 mg/dL or less (grade ≤1) within 10 days of denosumab initiation. In a prespecified interim analysis, 15 patients received denosumab (median CSC = 13.6 mg/dL). Time to response and response duration were analyzed with Kaplan-Meier methods. All statistical tests were two-sided. By day 10, 12 patients (80%; 95% exact confidence interval [CI] = 52% to 96%) responded (CSC ≤11.5 mg/dL); median response duration was 26 days. Ten patients (67%; 95% exact CI = 38% to 88%) had complete responses (CSC ≤10.8 mg/dL) by day 10. Denosumab may offer a new treatment option for HCM.

AB - Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In this single-arm, open-label, proof-of-concept study, HCM patients with albumin-corrected serum calcium (CSC) levels greater than 12.5 mg/dL (Common Terminology Criteria for Adverse Events grade ≥3) despite recent intravenous bisphosphonate treatment received subcutaneous denosumab on days 1, 8, 15, and 29, and then every 4 weeks. The primary endpoint was the proportion of patients with CSC 11.5 mg/dL or less (grade ≤1) within 10 days of denosumab initiation. In a prespecified interim analysis, 15 patients received denosumab (median CSC = 13.6 mg/dL). Time to response and response duration were analyzed with Kaplan-Meier methods. All statistical tests were two-sided. By day 10, 12 patients (80%; 95% exact confidence interval [CI] = 52% to 96%) responded (CSC ≤11.5 mg/dL); median response duration was 26 days. Ten patients (67%; 95% exact CI = 38% to 88%) had complete responses (CSC ≤10.8 mg/dL) by day 10. Denosumab may offer a new treatment option for HCM.

UR - http://www.scopus.com/inward/record.url?scp=84886921988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886921988&partnerID=8YFLogxK

U2 - 10.1093/jnci/djt225

DO - 10.1093/jnci/djt225

M3 - Article

VL - 105

SP - 1417

EP - 1420

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 18

ER -